This first randomized study in Brazzaville confirmed the excellent efficacy of these co-formulated anti-malarial drugs in children.
iNO at 80 ppm administered by non-rebreather mask was safe but did not affect circulating levels of Ang-2.
Aside from antimalarials, there is currently no treatment for cerebral malaria, a fulminant neurological complication of P. falciparum infection that is a leading cause of death in African children.
The most deadly complication of Plasmodium falciparum infection is cerebral malaria (CM) with a case fatality rate of 15–25% in African children despite effective antimalarial chemotherapy.
The protective efficacy of DHA/PQ chemoprevention in young children was strongly associated with higher drug exposure; in children with the highest PQ exposure, monthly DHA/PQ chemoprevention was nearly 100 % protective against malaria.
IPT alone only modestly decreased anaemia, but neither IPT nor iron fortified CF significantly improved Hb concentration after 9 months.
To investigate the prevalence and predictive value of hypoxaemia for deaths in under-5s with severe falciparum malaria infection.
Inclusion of 5 or 10 mg zinc in SQ-LNS and provision of 5 mg zinc dispersible tablet along with SQ-LNS had no impact on the incidence of diarrhoea, malaria and fever or the longitudinal prevalence of RTI compared with SQ-LNS without zinc in this population.
This study showed that the −403A mutation occurs in nearly half of the study population and the In1.1C allele occurs in one in every four children.
Despite high testing rates for malaria at all sites, prescription of anti-malarials to patients with negative test results remained high, with the exception of one site where a steady decline occurred.